Document is current
Any future updates will be listed below
-
Authors
Nie, Zhenyu
Liu, Bolong
Liu, Jinhui
Zu, Xiongbing
Wang, Juanhua
Chen, Jinbo
Fan, Benyi
Deng, Dingshan
-
Funding
Funding for this research was provided by:
China Postdoctoral Science Foundation (2024M753688)
Postdoctoral Fellowship Program of CPSF (GZC20233176)
Hunan Provincial Key Area Research Plan (2023SK2016, 2023SK2016)
Hunan Provincial Natural Science Foundation Science and Health Project (2022JJ70120)
Hunan Provincial Science Foundation (2019JJ40269)
National Nature Science Foundation of China (82303760)
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 17 September 2024
First Online: 27 September 2024
Declarations
:
: This study focuses on the secondary outcome of the trial “Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study” (Hu, J, Chen, J, Ou, Z, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study. Cell Rep Med. 2022; 3 []: 100785. doi: ). This study was approved by the Ethics Committees of all centers (ethical number: 202112241). The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Written informed consents were obtained from participants or their immediate families.
: All data presented in this publication are de-identifed and do not contain individual information.
: The authors declare no competing interests.
